<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686164</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-A001-109</org_study_id>
    <nct_id>NCT02686164</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, non-randomized Phase 1 study in participants with advanced
      solid tumors, excluding hepatocellular carcinoma (HCC), that have progressed after treatment
      with approved therapies, or for which there are no standard therapies available. The study
      will also include participants with radioiodine-refractory differentiated thyroid cancer
      (RR-DTC). Its primary intent is to determine the effect of lenvatinib on CYP3A4 activity as
      well as to assess the safety and activity of lenvatinib in these participants. The study will
      be conducted in the following 3 phases: Pretreatment Phase, Treatment Phase, and Extension
      Phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Actual">August 16, 2018</completion_date>
  <primary_completion_date type="Actual">January 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam</measure>
    <time_frame>Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam</measure>
    <time_frame>Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Lenvatinib + midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with histologically confirmed unresectable or refractory solid tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.</description>
    <arm_group_label>Lenvatinib + midazolam</arm_group_label>
    <other_name>Lenvima, E7080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.</description>
    <arm_group_label>Lenvatinib + midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years at the time of informed consent.

          2. Histologically or cytologically confirmed advanced solid tumors (excluding HCC) that
             have progressed following standard therapy, or for which no standard therapy exists
             (including surgery or radiation therapy) or participants with RR-DTC.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          4. Life expectancy greater than or equal to 3 months.

          5. Adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP less than or equal to 150/90 mmHg at screening and no
             change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1.

          6. Adequate renal function defined as calculated creatinine clearance greater than or
             equal to 30 mL/min per the Cockcroft and Gault formula.

          7. Adequate bone marrow function:

               1. Absolute neutrophil count (ANC) greater than or equal to 750/mm3 (greater than or
                  equal to 0.75 X 10^9/L)

               2. Platelets greater than or equal to 75,000/mm3 (greater than or equal to 75 X
                  10^9/L)

               3. Hemoglobin greater than or equal to 9.0 g/dL

          8. Adequate blood coagulation function as evidenced by an International Normalized Ratio
             (INR) less than or equal to 1.5.

          9. Adequate liver function:

               1. Total bilirubin less than or equal to 1.5 X the upper limit of normal (ULN)
                  except for unconjugated hyperbilirubinemia of Gilbert's syndrome

               2. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate
                  aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X
                  ULN if participant has liver metastases). If ALP is greater than 3 X ULN (in the
                  absence of liver metastases) or greater than 5 X ULN (in the presence of liver
                  metastases) AND the participant also is known to have bone metastases, the
                  liver-specific ALP must be separated from the total and used to assess the liver
                  function instead of total ALP.

         10. Participants with Hepatitis B or C are eligible on the condition that they have
             adequate liver function as defined by Inclusion Criterion 9.

         11. All prior therapy related toxicities must have resolved to Grade less than 2 severity
             per Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except
             alopecia and infertility.

         12. Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or
             multiple gated acquisition (MUGA) scan.

         13. Females must not be lactating or pregnant at screening or baseline (as documented by a
             negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of
             25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a
             negative screening pregnancy test was obtained more than 72 hours before the first
             dose of study drug.

         14. Participant must voluntarily agree to provide written informed consent.

         15. Participant must be willing and able to comply with all aspects of the protocol.

        Exclusion Criteria:

          1. Participants with diagnosis of HCC.

          2. Participants with anaplastic thyroid carcinoma with major blood vessel invasion or
             infiltration.

          3. Participants having greater than (&gt;) 1 plus (+) proteinuria on urine dipstick testing
             will undergo 24-hour urine collection for quantitative assessment of proteinuria.
             Participants with urine protein greater than or equal to (&gt;=1) gram per 24 hours will
             be ineligible.

          4. Participants with known leptomeningeal metastases or untreated brain metastases.
             Participants with known brain metastases will be eligible if they have completed the
             primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery, or
             complete surgical resection) and if they have remained clinically stable,
             asymptomatic, and off steroids for at least 28 days.

          5. Participants taking medications that are known potent CYP3A4 inducers/inhibitors or
             substrates with narrow therapeutic indices or St. John's Wort.

          6. Participants unwilling to exclude grapefruit juice and grapefruit from their diet.

          7. Participants who have received any anticancer treatment within 3 weeks or any
             investigational agent within 30 days before the first dose of study drug or who have
             not recovered from any acute toxicity greater than Grade 0 or 1 related to previous
             anticancer treatment.

          8. Major surgery within 4 weeks before the first dose of study drug.

          9. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled
             gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the
             bioavailability of lenvatinib or midazolam.

         10. Significant cardiovascular impairment: history of congestive heart failure greater
             than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension,
             unstable angina, myocardial infarction, or stroke within 6 months of the first dose of
             study drug; or cardiac arrhythmia requiring medical treatment (including oral
             anticoagulation).

         11. A clinically significant electrocardiogram (ECG) abnormality (ie, corrected QT
             interval [QTc] interval greater than 480 msec when electrolyte balance is normal), or
             a history of risk factors for torsade de pointes, hypokalemia, long QT syndrome, or
             the use of concomitant medications resulting in a prolongation of QTc interval.

         12. Active hemoptysis (bright red blood of at least 2.5 mL ie, half teaspoon) within 3
             weeks prior to the first dose of study drug.

         13. Active infection (any infection requiring treatment).

         14. Known hypersensitivity to any component of lenvatinib or midazolam.

         15. Prior treatment with lenvatinib.

         16. Achlorhydria or use of antacids, proton-pump inhibitors, or other drugs known to raise
             gastric pH within 2 weeks before study drug administration.

         17. Immunocompromised participants, including participants known to be infected with human
             immunodeficiency virus (HIV).

         18. Any other major illness that, in the investigator's judgment, will substantially
             increase the risk associated with the participant's participation in this study.

         19. Participants who meet any of the following criteria will be excluded from this study:

        Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
        positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG])
        test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent
        units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative
        screening pregnancy test was obtained more than 72 hours before the first dose of study
        drug.

        OR Females of childbearing potential who do not agree to use a highly effective method of
        contraception for the entire study period and for 28 days after study drug discontinuation
        i.e. i) total abstinence (if it is their preferred and usual lifestyle) ii) an intrauterine
        device (IUD) or hormone releasing system (IUS) iii) a contraceptive implant iv. an oral
        contraceptive (with additional barrier method) OR who do not have a vasectomized partner
        with confirmed azoospermia. For sites outside of the European Union (EU), it is permissible
        that if a highly effective method of contraception is not appropriate or acceptable to the
        participant, then the participant must agree to use a medically acceptable method of
        contraception, i.e. double barrier methods of contraception such as condom plus diaphragm
        or cervical/vault cap with spermicide. All females will be considered to be of childbearing
        potential unless they are postmenopausal [amenorrheic for at least 12 consecutive months,
        in the appropriate age group, and without other known or suspected cause] or have been
        sterilized surgically [i.e., bilateral tubal ligation, total hysterectomy, or bilateral
        oophorectomy, all with surgery at least 1 month before dosing]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <results_first_submitted>July 19, 2019</results_first_submitted>
  <results_first_submitted_qc>July 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenvatinib</keyword>
  <keyword>Lenvima</keyword>
  <keyword>E7080</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Midazolam</keyword>
  <keyword>CYP3A4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 4 investigative sites in the United States from 18 Apr 2016 to 16 Aug 2018.</recruitment_details>
      <pre_assignment_details>A total of 51 participants were screened and enrolled, of which 21 were screen failures and 30 participants received the study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Midazolam + Lenvatinib</title>
          <description>Participants received midazolam 4 milligram (mg) (2 milliliter [mL]) syrup, orally, once daily (QD), after an overnight fast on Day −3, Day 1 and Day 14 of Cycle 1 and lenvatinib 24 mg capsules, orally, QD, on each morning, continuously for 28 days of Cycle 1, starting on Day 1 of Cycle 1. Participants continued to fast for 2 hours postdose of midazolam. Duration of each cycle equal to (=) 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included participants who received at least 1 dose of midazolam or lenvatinib and had at least 1 postdose safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Midazolam + Lenvatinib</title>
          <description>Participants received midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day −3, Day 1 and Day 14 of Cycle 1 and lenvatinib 24 mg capsules, orally, QD, on each morning, continuously for 28 days of Cycle 1, starting on Day 1 of Cycle 1. Participants continued to fast for 2 hours postdose of midazolam. Duration of each cycle = 28 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam</title>
        <time_frame>Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)</time_frame>
        <population>Pharmacokinetic (PK) analysis set included participants who had sufficient PK data to derive at least 1 PK parameter. Here number analyzed “n” are the participants who were evaluable for this outcome measure for given categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 Day -3: Midazolam</title>
            <description>Participants received midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day−3 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 Day 1: Lenvatinib + Midazolam</title>
            <description>Participants received lenvatinib 24 mg capsules, orally, QD, in the morning and midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day 1 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Day 14: Lenvatinib + Midazolam</title>
            <description>Participants received lenvatinib 24 mg capsules, orally, QD, in the morning and midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day 14 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam</title>
          <population>Pharmacokinetic (PK) analysis set included participants who had sufficient PK data to derive at least 1 PK parameter. Here number analyzed “n” are the participants who were evaluable for this outcome measure for given categories.</population>
          <units>hour*nanograms per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Midazolam</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="34.5"/>
                    <measurement group_id="O2" value="89.7" spread="42.0"/>
                    <measurement group_id="O3" value="117" spread="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1’-hydroxymidazolam</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="26.5"/>
                    <measurement group_id="O2" value="48.6" spread="47.8"/>
                    <measurement group_id="O3" value="41.3" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC(0-24) of Midazolam: Cycle 1 Day 1, Lenvatinib (single-dose) + Midazolam Versus (vs.) Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.914</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.850</ci_lower_limit>
            <ci_upper_limit>0.983</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>AUC(0-24) of Midazolam: Cycle 1 Day 14, Lenvatinib (steady state) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.148</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.938</ci_lower_limit>
            <ci_upper_limit>1.404</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC(0-24) of 1’-hydroxy midazolam: Cycle 1 Day 1, Lenvatinib (single-dose) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.120</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.940</ci_lower_limit>
            <ci_upper_limit>1.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>AUC(0-24) of 1’-hydroxy midazolam: Cycle 1 Day 14, Lenvatinib (steady-state) + Midazolam vs.Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.199</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.057</ci_lower_limit>
            <ci_upper_limit>1.360</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam</title>
        <time_frame>Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)</time_frame>
        <population>PK analysis set included participants who had sufficient PK data to derive at least 1 PK parameter. Here number analyzed “n” are the participants who were evaluable for this outcome measure for given categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 Day -3: Midazolam</title>
            <description>Participants received midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day−3 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 Day 1: Lenvatinib + Midazolam</title>
            <description>Participants received lenvatinib 24 mg capsules, orally, QD, in the morning and midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day 1 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Day 14: Lenvatinib + Midazolam</title>
            <description>Participants received lenvatinib 24 mg capsules, orally, QD, in the morning and midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day 14 of Cycle 1. Participants continued to fast for 2 hours post dose of midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam</title>
          <population>PK analysis set included participants who had sufficient PK data to derive at least 1 PK parameter. Here number analyzed “n” are the participants who were evaluable for this outcome measure for given categories.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Midazolam</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="10.7"/>
                    <measurement group_id="O2" value="24.8" spread="17.4"/>
                    <measurement group_id="O3" value="28.3" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1'-hydroxy midazolam</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="8.64"/>
                    <measurement group_id="O2" value="12.7" spread="11.6"/>
                    <measurement group_id="O3" value="10.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Midazolam: Cycle 1 Day 1, Lenvatinib (single-dose) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.862</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.753</ci_lower_limit>
            <ci_upper_limit>0.988</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cmax of Midazolam: Cycle 1 Day 14, Lenvatinib (steady state) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.027</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.852</ci_lower_limit>
            <ci_upper_limit>1.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of 1’-hydroxy midazolam: Cycle 1 Day 1, Lenvatinib (single-dose) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.055</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.879</ci_lower_limit>
            <ci_upper_limit>1.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cmax of 1’-hydroxy midazolam: Cycle 1 Day 14, Lenvatinib (steady state) + Midazolam vs. Cycle 1 Day -3, Midazolam</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.940</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.845</ci_lower_limit>
            <ci_upper_limit>1.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)</time_frame>
        <population>Safety analysis set included participants who received at least 1 dose of midazolam or lenvatinib and had at least 1 postdose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Midazolam + Lenvatinib</title>
            <description>Participants received midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day −3, Day 1 and Day 14 of Cycle 1 and lenvatinib 24 mg capsules, orally, QD, on each morning, continuously for 28 days of Cycle 1, starting on Day 1 of Cycle 1. Participants continued to fast for 2 hours postdose of midazolam. Duration of each cycle = 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <population>Safety analysis set included participants who received at least 1 dose of midazolam or lenvatinib and had at least 1 postdose safety assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Midazolam + Lenvatinib</title>
          <description>Participants received midazolam 4 mg (2 mL) syrup, orally, QD, after an overnight fast on Day −3, Day 1 and Day 14 of Cycle 1 and lenvatinib 24 mg capsules, orally, QD, on each morning, continuously for 28 days of Cycle 1, starting on Day 1 of Cycle 1. Participants continued to fast for 2 hours postdose of midazolam. Duration of each cycle = 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Information</name_or_title>
      <organization>Eisai Inc.</organization>
      <phone>1-888-274-2378</phone>
      <email>esi_oncmedinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

